Category Archives: Psoriasis

Singer-songwriter Cyndi Lauper first joined Novartis Cosentyx team as a spokesperson more than four years ago, and the two are still churning out initiatives.

The latest is an unbranded awareness campaign to open up frank discussions about psoriasis stigma in the workplace.The effort, called PsO at Work, was inspired by psoriasis patients who have talked to Novartis over the past five years about the challenges of having psoriasis at work. Those include feeling embarrassed about visible plaques and flaking skin and the stigma caused by the inaccurate perception that the condition is contagious, a Novartis spokesman said in an email interview.

RELATED: In Novartis' newest Cosentyx push, active, real-life patients take center stage

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

PsO at Work aims to empower patients to feel comfortable speaking up about how psoriasis impacts them in the workplace and how they manage and deal with it, he said.

Lauper shares her own story online at PsOatWork.com and a social media effort encourages others to add their own experiences with the hashtag #PsOatWork.

Whether you are a performer, teacher or office manager, psoriasis can be a challenge at work and impact your ability to perform at your best," Lauper said in a press release. "Learning to figure out how to manage my psoriasis has allowed me to continue doing what I love while still standing out in the crowdbut not because of my psoriasis."

The unbrandedeffort comes on the heels of another round of Cosentyx branded TV ads, debuted recently, that include Lauper talking about her personal psoriasis journey over the past four years.

The new ads include several with Lauper and other real-life patients together and individually as they touttheir four or fiveyears of clear skin while using Cosentyx. The ads continue the "See Me" theme, begun three years ago.

The spokesman was clear that while Lauper appears in both campaigns, the two efforts are distinct and separate. Lauper has done other awareness work for Novartis previously,dating back to2015.

Although Cyndi does appear in branded advertisements, this (PoS at Work) initiative is about raising awareness of psoriasis and validating the experiences of people living with the condition, not drug. As the spokesperson for the campaign, Cyndi plays an important role as both an advocate and someone who has experienced the impact of psoriasis at work, he said.

RELATED:Lilly tees up another Novartis battle with ankylosing spondylitis OK for Taltz

Cosentyx was first approved in early 2015 to treat plaque psoriasis and added approved indications for ankylosing spondylitis and psoriatic arthritis in early 2016. Its chief competitor is Eli Lillys Taltz, another IL-17A inhibitor that now also compete in all three indications. With new phase 3 data in spondyloarthritis, Novartis is looking to make it four.

Read the original post:
Novartis, Cyndi Lauper shine a light on psoriasis challenges in the workplace - FiercePharma

Patients with psoriasis who do not receive proper disease education may not adhere to treatment, which can lead to worse outcomes, The American Journal of Managed Care reported. According to the article, a recent study examined the effect of an educational program on knowledge and self-expertise about psoriasis for patients with the disease. Patients were asked to fill out 2 questionnaires about disease knowledge, therapy adherence, and therapy satisfaction before and after the educational program. Overall, the educated patients showed a significant increase in knowledge, self-expertise about their disease, and general health after the program, the article reported.

Officials with the FDA declined to approve Adamis Pharmaceuticals opioid overdose treatment Zimhi, the company announced in a press release. According to Adamis, Zimhi, which is a naloxone pre-filled single-dose syringe, is designed to deliver high doses of naloxone for the emergency treatment of known or suspected opioid overdose. In a Complete Response Letter sent to the manufacturer, the FDA questioned the treatments manufacturing process, but not its safety or effectiveness, the release said.

A recent study suggests that antibiotic exposure may be linked to the risk of developing Parkinson disease, MD Magazine reported. According to the article, the study included 13,976 patients, as well as 40,697 control patients. Overall, the authors found that exposure to antianaerobics and tetracyclines 10 to 15 years before the index data, as well as suflonamides and trimethoprim 1 to 5 years before the index date and antifungal medication 1 to 5 years before the index date were positively associated with Parkinson disease risk, the article reported.

Read the original here:
Trending News Today: Patients with Psoriasis Benefit from Disease Education - Pharmacy Times

Novartis and thePsoriasis Association of Malaysia have launched the Be Pso Positive campaign in a bid to createreal world actions for enhancing the lives of those who take this medical condition in their stride and continue to pursue their individual aspirations and passion.

Done in collaboration with Edelman Malaysia and Malaysian singer and song writer Zee Avi, the latest spot is said to be the worlds first petition for Psoriasis heroes.Encouraged by the last years initiative of convincing Psoriasis patients to confidently face the limelight, this years collaboration pushes the envelope by kickstarting a petition to makePsoriasis treatment more accessible to all. Meanwhile, Edelman said the music video with Zee will roll out next week.Edelman Malaysias MD, Mazuin Zin, said music has the powerto both heal and make consumers feel for something that might not otherwise affect their lives.

A reason we decided to anchor our activism around scripting perhaps worlds first musical petition celebrating the lives of our Psoriasis heroes, their beliefs and aspirations. This truly is a demonstration how a brand walks the talk on its purpose in order to create an earned attention, she explained.

Mazuin added that the veryact of sitting down with those braving this medical condition and penning down their lifes aspirations with a professional lyricist brings out the key aspect that this medical condition is much deeper than a mere skin condition.

Through this musical journey we wish to educate both the sufferers and their care givers the aspect of how this condition can have much deeper manifestations in terms of psoriatic arthritis, cardiovascular diseases, diabetes and depression, among others, she added.

Excerpt from:
Novartis and Edelman create musical petition for Psoriasis heroes - Marketing Interactive

IMPORTANCE:

Psoriasis, a chronic inflammatory skindiseaseassociated with accelerated noncalcifiedcoronaryburden (NCB) bycoronarycomputed tomography angiography (CCTA), accelerates lipoprotein oxidation in the form of oxidized modified lipoproteins. A transmembrane scavenger receptor for these oxidized modified lipoproteins is lectinlike oxidized low-density lipoprotein receptor-1 (LOX-1), which has been reported to be associated withcoronary artery disease. It is unknown whether this receptor is associated withcoronary artery diseasein psoriasis.

To assess the association between soluble LOX-1 (sLOX-1) and NCB in psoriasis over time.

In a cohort study at the National Institutes of Health, 175 consecutive patients with psoriasis were referred from outpatient dermatology practices between January 1, 2013, and October 1, 2017. A total of 138 consecutively recruited patients with psoriasis were followed up at 1 year.

Circulating soluble lectinlike oxidized low-density lipoprotein receptor-1 levels were measured blindly by field scientists running undiluted serum using an enzyme-linked immunosorbent assay.

Coronarycomputed tomography angiography scans were performed to quantify NCB in all 3 major epicardialcoronaryarteries by a reader blinded to patient demographics, visit, and treatment status.

Among the 175 patients with psoriasis, the mean (SD) age was 49.7 (12.6) years and 91 were men (55%). The cohort had relatively low median cardiovascular risk by Framingham risk score (median, 2.0 [interquartile range (IQR), 1.0-6.0]) and had a mean (SD) body mass index (calculated as weight in kilograms divided by height in meters squared) suggestive of overweight profiles (29.6 [6.0]). Elevated sLOX-1 levels were found in patients with psoriasis compared with age- and sex-matched controls (median, 210.3 [IQR, 110.9-336.2] vs 83.7 [IQR, 40.1-151.0]; P<.001), and were associated with Psoriasis Area Severity Index (PASI) score (=0.23; 95% CI, 0.082-0.374; P=.003). Moreover, sLOX-1 was associated with NCB independent of hyperlipidemia status (=0.11; 95% CI, 0.016-0.200; P=.023), an association which persisted after adjusting for traditional cardiovascular risk factors, statin use, and biologic psoriasis treatment (=0.10; 95% CI, 0.014-0.193; P=.03). At 1 year, in those who had clinical improvement in PASI (eg, >50% improvement), a reduction in sLOX-1 (median, 311.1 [IQR, 160.0-648.8] vs median, 224.2 [IQR, 149.1 427.4]; P=.01) was associated with a reduction in NCB (=0.14; 95% CI, 0.028-0.246; P=.02).

Soluble lectinlike oxidized low-density lipoprotein receptor-1 levels were elevated in patients with psoriasis and were associated with severity of skindisease. Moreover, sLOX-1 associated with NCB independent of hyperlipidemia status, suggesting that inflammatory sLOX-1 induction may modulate lipid-rich NCB in psoriasis. Improvement of skindiseasewas associated with a reduction of sLOX-1 at 1 year, demonstrating the potential role of sLOX-1 in inflammatory atherogenesis in psoriasis.

The rest is here:
Association Between Soluble Lectinlike Oxidized Low-Density Lipoprotein Receptor-1 and Coronary Artery Disease in Psoriasis - DocWire News

It's an inflammatory, chronic skin condition that happens when your skin cells' natural turnover rate rapidly increasesresulting in dry, itchy, sometimes painful patches. It commonly appears on the elbows, knuckles, and scalp; it can, however, appear anywhere on the body.

The disease affects 8 million people in the United States and usually presents itself between 15 and 25, according to the National Psoriasis Foundation. We don't fully know what causes it, but it's related to the immune system, genetics, and environmental factors, Barr tells us.

"It's thought to be related to an immune system issue with T-cells, specifically T-regulator cells as well as other white blood cells, called neutrophils. While T-cells normally travel through the body to defend against foreign substances, such as viruses or bacteria, if you have psoriasis, the T-cells attack healthy skin cells as if to heal a wound or to fight an infection," Barr says. This triggers the increased production of healthy cells, resulting in the lesions. "Dilated blood vessels in psoriasis-affected areas also create warmth and redness," she says.

That's why it's vital to address inflammation in your treatment, as noted above.

More here:
Can You Treat Psoriasis Naturally? We Found The 5 Best Home Remedies - mindbodygreen.com

While guidelines for psoriatic arthritis recommend a treatment target of remission or low disease activity, consensus is lacking on how to define either. Disease activity is most often measured by DAPSA (Disease Activity index for Psoriatic Arthritis) scorebased mainly on jointsor VLDA/MDA (very low disease activity/minimal disease activity) criteriabased on assessment of joints, skin, and entheses. Previous research indicates that remission/low disease activity rates are higher with the use of DAPSA than with VLDA/MDA, according to Laure Gossec, MD, PhD, but what measurements with either test mean to patients is not well known.

For a study published in Annals of the Rheumatic Diseases, Dr. Gossec and colleagues surveyed patients with psoriatic arthritis of more than 2 years and compared their perceptions of remissions with those of their physicians and VLDA, LDA, and DAPSA scores.

In these patients not selected for good disease control and with usually long disease duration, remission or low disease activity were attained by more than 50% of patients, says Dr. Gossec. Patient-perceived remission/low disease activity was frequent (65.4%). Patient-perceived remission was as frequent as remission based on DAPSA, whereas good status according to VLDA/MDA was reached less frequently. DAPSA-based status appeared to correctly reflect patient-perceived low disease activity, which is an argument to use this score to assess psoriatic arthritis.

As the first to compare treatment targets using composite scores and patient questions on assessment of status, the cross-sectional study used a patient questionnaire developed for this study with patient research partners, but not externally validated. Dr. Gossec also notes that whether the findings would be replicated in patients over time is unknown. She adds, though, that physicians now have more information on patient perceptions of remission, and comparison with composite scores to follow-up patients; DAPSA appeared to agree more with patients assessments, though both scores have strengths and weaknesses.

Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countrieshttps://ard.bmj.com/content/78/2/201

Read the rest here:
Comparing Perceptions of Psoriatic Arthritis Disease Activity - Physician's Weekly

Several factors influence the choice of prescription systemic therapies for plaque psoriasis, with comorbidities and disease severity playing primary roles in clinical decision making, study findings published in the Journal of European Academy of Dermatology and Venereology suggest.

The Swiss Dermatology Network for Targeted Therapies registry in Switzerland was retrospectively reviewed for baseline data from patients with chronic plaque psoriasis who were included in the registry between March 2011 and December 2017. Only patients who had started a new systemic therapy for psoriasis were included in the analysis (n=549; mean age, 46.714.7 years). An a priori list of baseline variables and their associations with prescribed systemic therapies was assessed.

Patient variables associated with prescribing retinoids and methotrexate included having no prior history of systemic therapies, a moderate quality of life (QoL) at the onset of therapy, and age 60 years, according to a semantic connectivity map created by the investigators. Individuals with mild psoriasis (psoriasis area severity index [PASI] <10) and disease duration lasting 20 years were more likely to receive fumaric acid derivatives.

Severe chronic plaque psoriasis, characterized by impaired QoL, hospitalization, and inability to work, was associated with the use of cyclosporine and psoralen and ultraviolet A/ultraviolet light B (PUVA/UVB) therapies. Psoriatic arthritis, severe disease, and the presence of chronic liver or kidney diseases were associated with the use of both infliximab and adalimumab. Patients with a complex history of prior systemic treatments for psoriasis (2 therapies), moderate disease (PASI, 10 to 20), and patients who were overweight and had a university education were associated with the use of etanercept, ustekinumab, and secukinumab.

Study limitations include its exploratory and retrospective nature.

Some important comorbidities like psoriatic arthritis, chronic liver disease, and chronic kidney disease were found in the center of the map and in association with biological therapies, the researchers wrote, indicating that they may influence the choice of these treatments.

Disclosure: This clinical trial was supported by AbbVie, Celgene, Janssen, Lilly, Novartis and Pfizer. Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors disclosures.

Follow @DermAdvisor

Reference

Cazzaniga S, Anzengruber F, Augustin M, et al. Linkage between patients characteristics and prescribed systemic treatments for psoriasis: a semantic connectivity map analysis of the Swiss SDNTT registry [published online September 28, 2019]. J Eur Acad Dermatol Venereol. doi:10.1111/jdv.15983

Read more:
Patient Comorbidities and Severity of Psoriasis Correlate With Choice of Systemic Therapy - Dermatology Advisor

Over 125m people worldwide affected with psoriasis

Islamabad:Psoriasis drastically affects the everyday lives of patients as it victimizes more than 125 million people worldwide.

The Pakistan Psoriasis Foundation report states that in an analysis of survey data from 5,000 psoriasis patients, 20% of women said psoriasis was a massive problem in their everyday lives, compared to only 12 % of men. In addition, approximately 60 % of women said psoriasis interferes with their ability to enjoy life, as compared to only 52 per cent of men. Overall, women have greater difficulty dealing with the psychological and social issues brought about by having psoriasis.

Psoriasis is a chronic, inflammatory skin disease clinically evident as raised inflamed scaly red skin lesions that crack and itch. International Psoriasis Day is observed globally on October 29 to increase awareness of one of the most important skin problems. Psoriasis sufferers feel that people in general, including doctors, underestimate the overall impact the disease has on their lives. It is evident that the disease burden of psoriasis extends beyond the physical symptoms experienced by the patient.

Health professional and the general public should not minimize its impact as skin disorders are often chronic but not life threatening but they severely affect the mental well-being of patients. Psychologists who know the impact of the mental anxiety should come forward to help patients, opined Dr. Koukab Gulzar, Consultant Dermatologist at KRL Hospital.

Psoriasis can also cause inflammation of the joints, which is known as psoriatic arthritis. One-third of psoriatic patients have psoriatic arthritis. The risk for diabetes mellitus rises substantially in patients with psoriasis, with a 62% increase in risk noted in patients with severe psoriasis. Psoriasis appears to have a greater impact on womens lives and early cardiovascular deaths have been reported in psoriatic patients. Skin problems are generally the most common diseases seen in primary care settings all over the globe and its prevalence ranges from 20-50% in developing countries.

Psoriasis has a bimodal age of disease onset. The first peak is around 20 and the second peak is around 60. Around one-third of patients are under the age of 18 years. It is said that psoriasis has a genetic basis, as 23.4% to 71% of children will have a family history of psoriasis.

Originally posted here:
Over 125m people worldwide affected with psoriasis - The News International

1) As part of Brain Tumour Awareness Week 2019, Brain Tumour Ireland, in partnership with The Royal College of Surgeons in Ireland and Trinity College Dublin, are hosting a public lecture on Finding New Ways in the Lab to Tackle Glioblastoma with Dr Kate Connor PhD, RCSI Dept of Physiology and Medical Physics followed by two GLIOTrain Project PhD students who will give an update on their research and Brain Tumours and Epilepsy: Vital Links Provide Valuable Clues? with Prof Mark Cunningham PhD FTCD, Discipline of Physiology, School of Medicine, Trinity College. The event takes place on Wednesday, October 30th at Trinity Biomedical Sciences Institute, Pearse Street, Dublin 2 from 6.30pm to 8pm. It is a free event, but register your attendance by emailing info@braintumourireland.com or at eventbrite.ie

2) The UCD Centre for Arthritis Research second annual Collaborative Approach to Arthritis Research conference will take place on Friday, November 1st in St Andrews Resource Centre, Dublin 2. The theme this year is Transitions; from before to after diagnosis, from child to adult patient, from work to retirement. Attendance is free but registration is required. See eventbrite.ie

3) Returning for a fourth year to Dundrum Town Centre in Dublin, the Psoriasis Shout Out will see consultant dermatologists, dermatology nurses and patient advocates offer free, one-to-one medical advice and support for people living with psoriasis. With waiting lists to see a dermatologist in Ireland in excess of 18 months, the Shout Out is an opportunity to have an initial chat, get some advice and speak to a dermatologist. The free event takes place on Saturday, November 2nd from 9.30am to 4.30pm on the 3rd floor (beside Tesco) in the centre.

4) As Halloween approaches, people are being warned that novelty contact lenses are dangerous and pose a risk to those who wear them. The warning was issued by CORU, Irelands multi-profession health regulator. Novelty contact lenses may look like harmless fun, but the reality can be far more serious, said Ginny Hanrahan, CEO of CORU. Common problems associated with unsupervised use of contact lenses can include red, sore or dry eyes. Poor quality lenses or poor hygiene practises can also lead to far more serious complications including severe infections that in a worst case scenario could cause permanent blindness. We are strongly advising anyone considering novelty contact lenses as part of a Halloween costume not to wear them.

5) Researchers from the School of Psychology at NUI Galway are currently recruiting participants from ages 16-35 in the Galway area to participate in a new psychology therapy study being trialed for individuals who are in the first five years of a diagnosis of psychosis. Early psychosis, which refers to a range of mental health difficulties often associated with experiences of hallucinations or delusions, can result in significant difficulties with social and occupational functioning. The CReST-R study (Cognitive Remediation and Social Recovery in Early Psychosis Study) focuses on helping to improve everyday functioning in young people living with psychosis. The study will involve weekly one-to-one therapy sessions over the course of 10 weeks, with an assessment before and after completion of therapy. This trial is part of a Health Research Board funded programme entitled YOULEAD (Youth Mental Health Research Leadership) as part of a collaboration between mental health researchers at NUI Galway, UCD and RCSI, and health service providers, including the HSE and Jigsaw. To participate in the study and for more information contact Emma Frawley, crestr@nuigalway.ie, 086 8527199. For more information about YOULEAD, see nuigalway.ie/youlead

6) The Irish Hospice Foundation (IHF) is hosting its annual evening of remembrance on Thursday, November 7th. This is a free public information event allowing people to hear about aspects of loss and bereavement which may help them understand aspects of their own loss. Guest speaker, writer Emma Hayes will talk about Living with Loss following the death of her mother Karen. Emma wrote about her personal experience of grief in The Irish Times. The event takes place at the Alex Hotel, on Dublins Fenian Street from 5.30pm to 8pm. All are welcome to attend.

7) Dublin Rape Crisis Centre (DRCC) will host a one-day conference discussing Sexual Violence in Ireland: Past, Present and Future on Thursday, November 7th (9am-4.30pm) in the Royal College of Surgeons to mark their 40th anniversary. The conference will reflect on the origin and role of the centre. Tickets (10-25) are available via eventbrite.ie

8) Diabetes Ireland is hosting a free Health & Wellbeing Event for people living with, and at risk of, developing diabetes. The event will include exhibitors, workshops, diabetes products, the latest technology and free testing, and takes place at Limerick Strand Hotel from noon-5pm on Sunday, November 10th. Registration is not required.

9) As darkness sweeps around the globe on Wednesday, November 13th, 25,000 people in 50 cities worldwide will put on their running shoes to complete a 5k or 10k Run in the Dark - the principal fundraising event for the Mark Pollock Trust. Run in the Dark will take place in locations across Ireland - from Dingle to Dublin abd Wexford to Galway For more information go to runinthedark.org/ireland

10) A social singing event called Heres a health to the company: Social singing, health and well-being will take place at the Irish World Academy of Music and Dance, University of Limerick on Friday, November 15th. The special event is focused on the health and well-being benefits of social singing, from the perspectives of music therapy, community music, voice studies, traditional song, social justice and more. November 15th is World Music Therapy Day. To register see eventbrite.ie

11) Fighting Blindness Retina 2019 Public Engagement Day takes place during Science Week Ireland on Saturday, November 16th. The event offers people with sight loss an opportunity to quiz leading eye experts about their conditions, and to hear about the latest advances being made to improve and ultimately cure various types of sight loss. The conference will feature research-focussed breakout sessions on more than 20 rare conditions such as retinitis pigmentosa, diabetic retinopathy, age-related macular degeneration, cataracts, glaucoma and many more. Retina 2019 takes place in the Radisson Blu Hotel, Golden Lane, Dublin 8. For information on registration, visit retina.ie

12) The All Ireland Paediatric Diabetes Health Professional Conference 2019 takes place at Carlton Hotel, Dublin Airport from November 28th-29th. For more details, contact info@diabetes.ie, (01) 842 8118.

13) St Patricks Mental Health Services annual Founders Day conference on Friday, December 6th - at St Patricks University Hospital, Dublin 8 will focus on the theme of anxiety. The plenary lecture comes from Prof David Clark of Oxford University, who will be discussing effective psychological treatments for anxiety and the Improving Access to Psychological Therapies (IAPT) Programme. Prof Mark Freeston of Newcastle University will present on the role of intolerance of uncertainty in understanding, formulating and treating anxiety in anxiety disorders and beyond, while Prof Helen Kennerley of the Oxford Cognitive Therapy Centre will explore anxiety and dissociation. For more information and to book a place, visit stpatricks.ie/media-centre/events

For inclusion in these listings, email health@irishtimes.com with Health Board in the subject line

Follow this link:
Health Board: Upcoming conferences, talks, campaigns and events - The Irish Times

SAN DIEGO--(BUSINESS WIRE)--Clarify Medical announced today that it has closed an $18M Series A financing round with participation from H.I.G. BioHealth Partners, 7wire Ventures, SV Health Investors, and Bluestem Capital. The proceeds of the round will be used for the commercialization and further development of the Clarify Home Light Therapy System for the treatment and monitoring of patients with chronic skin conditions.

Michael Wasserman, Managing Director of H.I.G. BioHealth Partners; Robert Garber, Partner at 7wire Ventures; and Paul LaViolette, Managing Partner and Chief Operating Officer of SV Health Investors, will join the companys board of directors, effective immediately.

Clarify Medical has attracted a strong syndicate of leading medical technology and digital health investors to fuel its commercialization efforts, said Dr. Wasserman. The significant technological advances of the Clarify System will enable patients with chronic skin diseases like psoriasis, vitiligo, and eczema to safely and effectively manage their conditions at home, while remaining connected to their physicians via Clarifys cloud connectivity. The approach has tremendous benefit for patients, physicians and healthcare providers.

The Clarify System, which has been cleared by the FDA, is indicated for localized phototherapeutic treatment of dermatologic conditions such as psoriasis, vitiligo, atopic dermatitis (eczema), seborrheic dermatitis, and leukoderma on all skin types (I-VI). It is the first and only connected phototherapy system that uses an app on the patients own smartphone (iOS or Android) to manage the dose, frequency, and duration of targeted narrowband UVB (NB-UVB) light therapy; the System helps to ensure that patients receive the proper doses recommended by the American Academy of Dermatology in its published Guidelines of Care for the Management of Psoriasis and Psoriatic Arthritis and The Vitiligo Working Group Recommendations for NarrowBand Ultraviolet B Light Phototherapy Treatment of Vitiligo.

The treatment regimen is prescribed by the patients physician but monitored and controlled by the Clarify System, enabling patients to administer treatment with clinical precision and achieve clinical efficacy in the convenience of their homes. The connected system monitors dosing, adherence, compliance, patient progress, and satisfaction.

There are 30 million people in the U.S. with psoriasis, vitiligo, and eczema and approximately 5,400 medical dermatologists who help these patients treat and manage their conditions.

We are very pleased to have such high-caliber investors join our board, said George Mahaffey, President & CEO of Clarify Medical. In the brief time the Clarify System has been commercially available, weve established Medicare coverage and have helped many patients self-manage their chronic skin conditions at home. With this funding, we are now poised to fully launch the System in the U.S. by improving market access and building awareness within the medical dermatology community that there is now a home phototherapy option that patients can use safely and effectively.

About Clarify Medical, Inc.

Clarify Medical is a private San Diego-based medical device company focused on developing innovative technology, products, and services that improve care for people with chronic skin conditions. Its Clarify Home Light Therapy System is now available nationally in the U.S. Learn more at http://www.clarifymed.com.

More here:
Clarify Medical Closes $18M Series A Round to Commercialize its Connected Home Phototherapy System in the U.S. - Business Wire